Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 10/20 | 0.51 |
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497728 | 0.82 | MAOB (0.51) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL6768284 | 0.81 | MAOB (0.48) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL3372411 | 0.80 | MAOB (0.64) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL9007487 | 0.78 | MAPT (0.80) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL8354843 | 0.73 | HTR2A (0.47) | MAPTL3MBTL1MAPK1MAOACYP2C9 | |
| SCHEMBL19612191 | 0.73 | MAPT (1.00) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL29846180 | 0.72 | KCNA3 (0.49) | MAOBMAOAKCNA3 | |
| SCHEMBL28905201 | 0.72 | KCNA3 (0.49) | MAOBMAOAKCNA3 | |
| SCHEMBL31091535 | 0.72 | MAOB (0.50) | L3MBTL1MAPK1MAOBMAOAACHE | |
| SCHEMBL15349084 | 0.72 | MAOB (0.50) | L3MBTL1MAPK1MAOBMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | MAPT 448/4885TDP1 2051/4885L3MBTL1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.